Condition: Relapsed or Refractory Multiple Myeloma · Sponsor: Celgene
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0366 | Los Alamitos, California, United States | Active Not Recruiting |
| Local Institution - 0272 | San Diego, California, United States | Completed |
| Local Institution - 0273 | West Hollywood, California, United States | Completed |
| Local Institution - 0381 | Aurora, Colorado, United States | Not Yet Recruiting |
| Local Institution - 0380 | Farmington, Connecticut, United States | Completed |
| Local Institution - 0208 | New Haven, Connecticut, United States | Withdrawn |
| Local Institution - 0303 | Coral Springs, Florida, United States | Active Not Recruiting |
| Local Institution - 0403 | Fort Myers, Florida, United States | Active Not Recruiting |
| Local Institution - 0401 | St. Petersburg, Florida, United States | Active Not Recruiting |
| Local Institution - 0402 | West Palm Beach, Florida, United States | Active Not Recruiting |
| Local Institution - 0211 | Athens, Georgia, United States | Active Not Recruiting |
| Local Institution - 0048 | Marietta, Georgia, United States | Withdrawn |
+ 254 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05519085